Sagent Pharmaceuticals acquires Omega Laboratories

Sagent Pharmaceuticals, Inc., a leader of specialty pharmaceutical products with an emphasis on the injectable market, completed its acquisition of Omega Laboratories Limited, a market leading specialty pharmaceutical company based in Montreal, for approximately US$85.3 million (C$95 million) in cash. The combination of Sagent and Omega creates a premier generic injectable company with a robust product portfolio, deep development pipeline and strong global presence.


Sagent was represented in the US by Alexander Fine and George Stamas of
Kirkland & Ellis LLP; and in Canada by Brian Pukier, Kim Le and Julien Lefebvre (M&A); John Lorito, Katy Pitch and Dominic Bédard-Lapointe (tax); Stephanie Weschler and Frédéric Henry (employment); Richard Rusk (environmental); Neil Bindman (real estate) and Ashley Piotrowski (competition) of Stikeman Elliott LLP.

Omega was represented by Fasken Martineau DuMoulin LLP with a team led by Patrice Vachon, and including Marie-Eve Clavet, Kiran Singh, Anabel Quessy, Joëlle Simard, Pierre-Olivier Charlebois, Emilie Bundock and Alain Ranger.

Lawyer(s)

Brian M. Pukier Kim Le John G. Lorito Katy Pitch Stephanie Weschler Frédéric Henry Richard J. Rusk Neil L. Bindman Patrice Vachon Pierre-Olivier Charlebois Alain Ranger